Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director · President | June 30, 2021 | July 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 573,007 |
Reported balance
After 2021-06-30 transaction · row 1
1 source rowRow 1 · 2021-06-30 · Sale · Disposed 25,000 · Balance 573,007 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2019 Filed Jan 10, 2019 21:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 82,690 | $35.01 | $2,894,976.90 |
DisclosureSEC source: 0000899243-19-000956 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,048,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.105, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:09 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 17,310 | $35.09 | $607,407.90 |
DisclosureSEC source: 0000899243-19-000956 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,697 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,760 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,240 Underlying: Common Stock · 39,760 shares Expires 2016-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,240 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · derivative · entry 4 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,586 Underlying: Common Stock · 35,240 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 75,000 | $60.00 | $4,500,000.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 39,760 | $14.00 | $556,640.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 35,240 | $1.81 | $63,784.40 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,853 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-021477 · doc4.xml · derivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,826 Underlying: Common Shares · 3,853 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,853 | $20.33 | $78,320.32 |
DisclosureSEC source: 0000899243-17-021477 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.60, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,853 | $1.81 | $6,973.93 |
DisclosureSEC source: 0000899243-17-021477 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 14,617 | $20.87 | $305,072.87 |
DisclosureSEC source: 0000899243-17-021477 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.46 to $21.26, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,722 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,679 Underlying: Common Shares · 5,722 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 58,103 | $20.31 | $1,179,949.91 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162,624 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.88, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,722 | $1.81 | $10,356.82 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,692 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,401 Underlying: Common Shares · 17,692 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 17,692 | $20.06 | $354,919.21 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.88, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 22:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 17,692 | $1.81 | $32,022.52 |
DisclosureSEC source: 0000899243-17-021281 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,825 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-017094 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,093 Underlying: Common Shares · 10,825 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,825 | $15.37 | $166,387.83 |
DisclosureSEC source: 0000899243-17-017094 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.59, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,825 | $1.81 | $19,593.25 |
DisclosureSEC source: 0000899243-17-017094 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,578 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · derivative · entry 9 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,918 Underlying: Common Shares · 11,578 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 21, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 11,578 | $15.02 | $173,845.99 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 11,578 | $1.81 | $20,956.18 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,252 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · derivative · entry 8 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,496 Underlying: Common Shares · 3,252 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,252 | $15.00 | $48,784.88 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.01, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,252 | $1.81 | $5,886.12 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,392 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · derivative · entry 7 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,748 Underlying: Common Shares · 15,392 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,392 | $15.00 | $230,880.00 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.12, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 15,392 | $1.81 | $27,859.52 |
DisclosureSEC source: 0000899243-17-016873 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Options (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-17-016674 · doc4.xml · derivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Shares · 270,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 270,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning July 15, 2017. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,140 Underlying: Common Shares · 1,100 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,100 | $15.08 | $16,583.05 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.13, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 1,100 | $1.81 | $1,991.00 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,203 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,240 Underlying: Common Shares · 4,203 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,203 | $15.00 | $63,045.00 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 4,203 | $1.81 | $7,607.43 |
DisclosureSEC source: 0000899243-17-016100 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,650 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,443 Underlying: Common Shares · 3,650 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,650 | $15.02 | $54,828.84 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,650 | $1.81 | $6,606.50 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,923 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,093 Underlying: Common Shares · 25,923 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 25,923 | $16.03 | $415,576.80 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $16.56, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,923 | $1.81 | $46,920.63 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 24,077 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,016 Underlying: Common Shares · 24,077 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 24,077 | $16.50 | $397,282.54 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 24,077 | $1.81 | $43,579.37 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 616 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,093 Underlying: Common Shares · 616 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 616 | $16.92 | $10,425.68 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.76 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 616 | $1.81 | $1,114.96 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Options (Right to Buy) · Derivative | 13,191 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 10 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,709 Underlying: Common Shares · 13,191 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 04, 2017 Filed May 4, 2017 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 13,191 | $16.37 | $215,960.41 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 7 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.78, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.